肝硬化及原发性肝癌患者血清半胱氨酸蛋白酶抑制剂C水平的改变及其意义

检验医学 ›› 2012, Vol. 27 ›› Issue (2): 118-121.

肝硬化及原发性肝癌患者血清半胱氨酸蛋白酶抑制剂C水平的改变及其意义

第二军医大学东方肝胆外科医院实验诊断科，上海 200438

出版日期:2012-02-28 发布日期:2012-02-19
通讯作者: 高春芳，联系电话：021-81875131。
作者简介:王　坤，男，1982年生，学士，技师，主要从事临床生化工作。
基金资助:
上海市科学委员会科研计划资助项目（No.10411955200）

The change of serum cystatin C level in patients with liver cirrhosis and primary liver carcinoma and its significance

Department of Laboratory Medicine，Eastern Hepatobiliary Hospital，Second Military Medical University，Shanghai 200438，China

Online:2012-02-28 Published:2012-02-19

摘要/Abstract

摘要： 目的　探讨血清半胱氨酸蛋白酶抑制剂C (Cys C) 水平在肝硬化和原发性肝癌（PLC）患者中的变化及其临床意义。方法　采用胶乳增强免疫透射比浊法测定90例肝硬化、153例PLC及95例肝脏良性病变患者（对照组，包括肝血管瘤、肝囊肿）血清Cys C水平，同时采用酶法检测血清肌酐（SCr）及尿素（Urea）水平。分析Cys C、SCr、Urea在肝硬化、PLC和对照组间的差异以及Cys C与SCr、Urea之间的相关性。按照ChildPugh标准对肝硬化患者的肝功能进行分级，对肝功能不同等级间Cys C、SCr、Urea水平进行比较。结果　肝硬化组血清Cys C水平为（1.04±0.24）mg/L，肝癌组为（0.98±0.28）mg/L，均高于对照组［(0.78±0.18) mg/L］（P<0.001），肝硬化组亦高于肝癌组（P<0.05）。肝硬化组和肝癌组Urea和SCr水平无明显差异，但均明显高于对照组（P<0.05）。血清Cys C与SCr呈正相关（肝硬化、肝癌和对照组的r值分别为0.407、0.673、0.511，（P均<0.001）。肝硬化组和肝癌组中血清Cys C异常率均明显高于SCr及Urea（P均<0.001）。肝硬化ChildPugh B+C级血清Cys C水平［(1.12±0.21)mg/L］显著高于ChildPugh A级［(0.99±0.25) mg/L］(P<0.05)。结论　血清Cys C水平随着肝病的进展和患者肝功能的衰退而升高，且比SCr和Urea更能灵敏的反映慢性肝病患者的早期肾损伤。

关键词: 半胱氨酸蛋白酶抑制剂C, 肌酐, 尿素, 肝硬化, 原发性肝癌, 肾功能

Abstract: Objective　To investigate the change and clinical significance of serum cystatin C (Cys C) level in patients with liver cirrhosis and primary liver carcinoma (PLC). Methods　Serum Cys C levels were detected in 90 cases of liver cirrhosis， 153 cases of PLC and 95 cases of benign liver disease(liver hemangioma and hepatic cyst) as controls by latex particle enhanced immunoturbidimetry， while serum creatinine (SCr) and urea were detected by enzymic method. The differences of serum Cys C， SCr and urea levels and their relationship were analyzed between the groups. The Cys C, SCr and urea levels were analyzed according to the liver function ChildPugh grade. Results　Serum Cys C level was significantly higher in liver cirrhosis group ［(1.04±0.24) mg/L］ and PLC group ［(0.98±0.28) mg/L］ than that in control group ［(0.78±0.18) mg/L］， (P<0.001)， and the Cys C level in liver cirrhosis group was higher than that in PLC group (P<0.05). Serum SCr and urea levels in liver cirrhosis and PLC groups were also significantly higher than that in control group (P<0.05)， but there was no significant difference between liver cirrhosis and PLC groups. There was significant positive correlation between serum Cys C and SCr levels (liver cirrhosis group: r=0.407, PLC group: r=0.673 and control group: r=0.511, P<0.001). The abnormal rates of Cys C were significantly elevated in both liver cirrhosis and PLC groups than those of SCr and urea (P<0.001). Serum Cys C level was significantly higher in ChildPugh B+C group ［(1.12±0.21) mg/L］ than that in ChildPugh A group ［(0.99±0.25) mg/L］ among the liver cirrhosis group(P<0.05). Conclusions　Serum Cys C increases with the progression of liver disease and severity of liver failure， and it indicates early renal disfunction better than SCr and urea in patients with chronic liver disease.

Key words: Cystatin C, Creatinine, Urea, Liver cirrhosis, Primary liver carcinoma, Renal function

王坤;房萌;赵琳;蔡美琳;高春芳. 肝硬化及原发性肝癌患者血清半胱氨酸蛋白酶抑制剂C水平的改变及其意义[J]. 检验医学, 2012, 27(2): 118-121.

WANG Kun;FANG Meng;ZHAO Lin;CAI Meilin;GAO Chunfang. The change of serum cystatin C level in patients with liver cirrhosis and primary liver carcinoma and its significance[J]. , 2012, 27(2): 118-121.

[1]	俞琪, 王砚春, 郭林, 卢仁泉. 粒子放疗对前列腺癌患者骨髓、肝和肾功能的影响[J]. 检验医学, 2023, 38(5): 430-434.
[2]	李莲, 黄晓玲, 姚娟. 高浓度肌酸致血清肌酐酶法检测结果假性升高病例分析[J]. 检验医学, 2023, 38(5): 497-501.
[3]	顾刚, 欧维正, 陶铜芳, 董江义. 改良肌氨酸氧化酶法肌酐试剂抗高IgM干扰分析[J]. 检验医学, 2023, 38(3): 294-296.
[4]	顾怡, 王蕊, 邓杰, 杨易静, 周王柯, 陈予诺, 陈小松, 沈薇, 周景艺. 重症肝炎和肝硬化患者肝移植前后生物标志物水平差异及其预后评估价值[J]. 检验医学, 2023, 38(11): 1044-1051.
[5]	戴健敏, 陈诺, 魏坚. 慢性肾脏病不同阶段患者血清ProGRP、NSE、CYFRA21-1水平的变化[J]. 检验医学, 2022, 37(9): 811-814.
[6]	吴苏君, 冀恒涛, 彭梦乐. IL-18、IL-37、NLRP3及NK/DC比值在乙型肝炎相关肝硬化中的临床价值[J]. 检验医学, 2022, 37(6): 518-523.
[7]	张水检, 周琰, 邵文琦, 张春燕, 潘柏申, 王蓓丽, 郭玮. 半定量干化学法检测尿白蛋白/肌酐比值的临床应用价值[J]. 检验医学, 2022, 37(5): 463-465.
[8]	刘文霞, 王玮, 林松洋, 李振红. 不同增强剂对荧光PCR中尿素、血红素和胆酸盐抑制作用消除效果研究[J]. 检验医学, 2022, 37(2): 155-158.
[9]	黄思聪, 石永杰, 嘉红云. FK506、肾功能指标及单个核细胞计数判断肾移植患者尿BKV DNA阳性的价值[J]. 检验医学, 2021, 36(8): 837-842.
[10]	程惠芬. 血清P-选择素、ICAM-1、IL-17A水平在HBV感染相关疾病中的临床价值[J]. 检验医学, 2021, 36(6): 646-649.
[11]	刘非, 胡炎伟. 分析前因素对血清肾功能检测项目测定结果的影响[J]. 检验医学, 2021, 36(4): 369-373.
[12]	邵文琦, 于正麟, 吴群, 张春燕, 王蓓丽, 潘柏申, 郭玮. 盐酸利多卡因致血清干化学肌酐定量结果异常1例报道[J]. 检验医学, 2021, 36(4): 381-383.
[13]	张卫威, 景蓉蓉, 季伙燕, 王建新, 王峰, 王惠民. 同位素稀释质谱法测定血清肌酐浓度的不确定度评定[J]. 检验医学, 2021, 36(3): 263-269.
[14]	刘婷婷, 林玉婷, 米拉, 李晓勤. 血清IL-33水平及其基因多态性与HBV感染临床转归的相关性[J]. 检验医学, 2021, 36(11): 1101-1105.
[15]	徐文俊, 李甲勇, 李会丹. 不同eGFR公式与ACR联合应用在肾功能损伤高危人群中的临床价值[J]. 检验医学, 2021, 36(1): 13-19.